Table of Contents
ISRN AIDS
Volume 2013 (2013), Article ID 358294, 10 pages
http://dx.doi.org/10.1155/2013/358294
Research Article

Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy

1Department of Microbiology and Immunology, McGill University Health Centre, Room A5-140, 1650 Cedar Avenue, Montreal, QC, Canada H3G 1A4
2Montreal General Hospital, Flowcytometry Laboratory, 1650 Cedar Avenue, Room C10-166, Montreal, QC, Canada H3G 1A4
3LAC+USC Medical Center, 1200 N State Street, Room IPT-C4E100, Los Angeles, CA 90033, USA
4Janssen Services, LLC, Clinical Affairs, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA

Received 12 August 2013; Accepted 17 November 2013

Academic Editors: G. D'ettorre and C. Petrovas

Copyright © 2013 Christos Tsoukas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Christos Tsoukas, Louise Gilbert, Trevor Lewis, George Hatzakis, Ron Falcon, and Joseph Mrus, “Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy,” ISRN AIDS, vol. 2013, Article ID 358294, 10 pages, 2013. doi:10.1155/2013/358294